We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Find trade remedies notices published from February 2020.
Find out about changes to the Business Investment Relief rules from 6 April 2017.
Guidance for local authorities and fire and rescue services on the use remediation orders, a Building Safety Act 2022 enforcement power.
Read about talking therapies and counselling for mental health problems.
Advice for medical professionals to follow when assessing drivers with visual disorders.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
The eyesight rules to pass your driving test and for whenever you're driving.
Urgent safety updates arising from pharmacovigilance data, including reported adverse events, for veterinary medicines authorised in the UK.
How the government monitors imports into the UK.
Actions that trial sponsors should consider to build resilience into clinical trial design
Explains testing from 1 April 2024 onwards and sets out the purpose of ongoing testing, who will be eligible to access testing and when tests should be used.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 April 2024) approved the medicine fosdenopterin (Nulibry) to treat the genetic disease Molybdenum Cofactor Deficiency (MoCD) Type A
Information for those who have been prescribed Paxlovid.
Neon Healthcare Ltd is recalling the specific batch mentioned in this notification as a precautionary measure.
Information on service related illnesses, recovery and healthcare services.
There are different regulations which apply to devices and equipment including hand gels and PPE (personal protective equipment)
The review of the safety of isotretinoin has concluded.
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
You can claim relief to pay no Customs Duty and VAT if you're importing therapeutic substances of human origin, blood-grouping or tissue-typing reagents, or related packaging, solvents and accessories.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).